Cidara Therapeutics

6310 Nancy Ridge Drive Suite 101
San Diego, CA 92121
United States

Tel: (858) 752-6170

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). Cidara is also advancing a second Phase 3 trial of once-weekly rezafungin for prophylaxis against invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) initially in Europe and Canada. In addition to its robust rezafungin clinical program, Cidara is applying its proprietary Cloudbreak® platform to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases. The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patient’s immune system to attack and eliminate pathogens. Cidara is headquartered in San Diego, California.

214 articles about Cidara Therapeutics

Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

3/3/2023

Cidara Therapeutics, Inc. today announced the pricing of concurrent but separate underwritten public offerings of 9,640,000 shares of its common stock and 286,000 shares.
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock

3/2/2023

Cidara Therapeutics, Inc. announced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock.
Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

3/1/2023

Cidara Therapeutics, Inc. today announced promising efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain, as of a February 13, 2023 data cut-off.
Cidara to Present at ESMO Targeted Anticancer Therapies Congress

2/28/2023

Cidara Therapeutics, Inc. today announced that it will present highlights from pharmacokinetic studies of a CD73-targeting drug-Fc conjugate (DFC) oncology candidate from the Company’s Cloudbreak ® platform at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023.
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - February 14, 2023

2/14/2023

Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, announced that it has received formal notice from The Nasdaq Stock Market, LLC, stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.
Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program

2/1/2023

Cidara Therapeutics, Inc. and WuXi XDC announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug -enabling chemistry, manufacturing and controls development services for Cidara’s CD73 oncology DFC program.
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

1/25/2023

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA).
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® PlatformCBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target

1/4/2023

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has selected its first oncology drug-Fc conjugate (DFC) candidate from the company’s Cloudbreak® platform: CBO-212, targeting CD73.
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388Initial CD388 clinical data expected in the first half of 2023

12/1/2022

Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,510,992, entitled Compositions and Methods for the Treatment of Viral Infections, for CD388, a highly potent, long-acting drug-Fc conjugate (DFC) designed to achieve universal prevention of seasonal and pandemic influenza.
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

11/29/2022

Cidara Therapeutics, Inc. announced that Institutional Shareholder Services and Glass Lewis and Co, LLC, two leading, independent proxy advisory firms, have both recommended that stockholders vote “FOR” the proposed reverse stock split at the Company’s upcoming Special Meeting of Stockholders, scheduled for Thursday, December 15, 2022 at 8:00 a.m. PST.
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

11/28/2022

Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis.
Cidara Therapeutics to Participate in the World Antiviral Congress 2022

11/23/2022

Cidara Therapeutics, Inc. today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.
Cidara Therapeutics to Present at the Stifel Healthcare Conference

11/8/2022

Cidara Therapeutics, Inc. announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference.
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

11/3/2022

Cidara Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided an update on its corporate activities and product pipeline.
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

10/17/2022

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it is presenting new clinical and preclinical data for rezafungin in six poster presentations at IDWeek taking place in-person in Washington, D.C. from October 19-23, 2022.
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

10/4/2022

Cidara Therapeutics, Inc. announced receipt of an $11 million milestone payment from Mundipharma under the licensing agreement established between the two companies in September 2019.
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive CandidiasisAssigned PDUFA target action date of March 22, 2023

9/20/2022

Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to its New Drug Application (NDA) for rezafungin for the treatment of candidemia and invasive candidiasis.
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza

9/13/2022

Cidara Therapeutics, Inc. today announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza.
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

9/6/2022

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the 24th Annual H.C. Wainwright Global Investment Conference.
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

8/9/2022

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its corporate activities and product pipeline.